TD Cowen analyst Charles Rhyee raised the firm’s price target on CVS Health (CVS) to $95 from $90 and keeps a Buy rating on the shares. The firm said 1Q25 represents a return to a beat and raise pattern and they see multiple areas of conservatism in its guidance.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- Cigna price target raised to $390 from $379 at Morgan Stanley
- CVS Health’s Positive Trajectory: Outperform Rating Reaffirmed with Raised Price Target
- CVS Health price target raised to $71 from $67 at UBS
- Eli Lilly selloff on CVS Wegovy news overdone, says JPMorgan
- CVS Health price target raised to $85 from $80 at BofA